Exelixis Q1 revenue $610.8M, GAAP EPS $0.79; announces $750M buyback

EXELIXIS, INC.

2026-Q1 EPS reported $0.79 revenue$610,812,000

Total revenues $610.8M (+10% YoY); cabozantinib U.S. net product revenue $555.0M.
GAAP diluted EPS $0.79 (vs. $0.55 in Q1 2025); non-GAAP diluted EPS $0.87.
Board authorized new $750M stock repurchase program through Dec 31, 2027.
Zanzalintinib NDA accepted for colorectal cancer; PDUFA target Dec 3, 2026.
Company plans to complete current $750M buyback this month.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

EXELIXIS, INC. reported first quarter of 2026 results: revenue $610.8 million, net income $210.5 million, EPS $0.79 per share, diluted.

Period: first quarter of 2026
Revenue: $610.8 million
Net income: $210.5 million
EPS: $0.79 per share, diluted
Result: reported results

Exact text from the filing

& Investor Relations Exelixis, Inc. 650-837-7248 apeters@exelixis.com Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update - Total Revenues of $610.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $555.0 million - - GAAP Diluted EPS of $0.79, Non-GAAP Diluted EPS of $0.87 - - Announced Additional Stock Repurchase Program

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

EXELIXIS, INC. filing history →

Source: SEC EDGAR

accession 0000939767-26-000058

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.